Migraine Therapy

Iron Infusions
IV Infusions

Monoclonal Antibodies
IV Infusions & SQ Injections

Bone Modifying Agents
IV Infusions & SQ Injections

Blood Transfusions

Therapeutic Phlebotomy

Albumin Infusions

Line/Port Care Services

IV Hydration and Electrolytes

Immunocompromised Therapy

Hematology
Colony Stimulating Factors SQ

and many more services available

All infusion services:
Require insurance authorization prior to scheduling and administration of the medication(s).

Only medications approved by the INTEGRIS Health Formulary Integration Committee will be accepted and administered to patients by the INTEGRIS Health Ponca City Hospital Outpatient Infusion Center.

INTEGRIS HEALTH
Ponca City Hospital

1044288

Outpatient Infusion Center

INTEGRIS Health Ponca City Hospital Outpatient Infusion Center proudly serves Ponca City and surrounding areas.

INTEGRIS HEALTH
Ponca City Hospital

1900 N 14th St.
Ponca City, OK 74601
P: 580-763-3041 • F: 580-763-0892

Migraine Treatment

IV Infusions

- Vyepti (eptinezumab-jjmr)
  Preventative if 4+ migraines/month

Bone-Modifying Agents

IV Infusions and SQ Injections

Available SQ Injections

- Prolia (Denosumab)
- Xgeva (Denosumab)
- Evenity (Romosozumab)

Available IV Infusions

- Boniva (Ibandronate)

Others may be available upon approval.

Immunoglobulins

- Privigen IVIG
- Gamunex- C IVIG

Hematology

Colony Stimulating Factors: Multiple agents available:

- Erythropoietin
- Pegfilgrastim
- Filgrastim
- and others

Iron Infusions

IV Infusions

Preferred for CKD

- Feraheme (Ferumoxytol)+
- Injectafer (Ferric Carboxymaltose)
- Venofer (Iron Sucrose)
  +Formulary preferred product.

Preferred for Pregnancy

- Venofer (Iron Sucrose)

FDA-Approved for Iron Deficiency in Whom Oral is Unsatisfactory or Impossible

- Feraheme (Ferumoxytol)+
- INFeD (Iron Dextran)
- Injectafer (Ferric Carboxymaltose)
  +Formulary preferred product.

Dosing considerations suggestions

- Injectafer – two doses separated by ≥ seven days OR one dose of 15 mg/kg (max 1 g)
- Feraheme – two doses of 510 mg separated by ≥ three days OR one dose of 1.02 g
- INFeD – Requires a test dose of 25 mg followed by a one-hour observation to ensure the patient does not have an anaphylactic reaction.
- Venofer - 100 to 200 mg IVP, may repeat 1 - 4 over 14 days.

Monoclonals

IV Infusions and SQ Injections

Available SQ Monoclonals

- Cimzia (Certolizumab)
  Rheumatoid Arthritis/Psoriasis
- Fasenra (benralizumab)
  Severe Asthma
- Ilumya (tildrakizumab-asmn)
  Plaque Psoriasis
- Simponi (Golimumab)
  Rheumatoid Arthritis/Ulcerative Colitis/Psoriasis

Available IV Monoclonals

- Actemra (tocilizumab)
  Rheumatoid Arthritis
- Benlysta (Belimumab)
  Lupus
- Entyvio (Vedolizumab)
  Ulcerative Colitis
- Inflectra (inFLIXimab-DYYB)
  Rheumatoid Arthritis/Psoriasis
- Remicade (InFLIXimab)
  Ulcerative Colitis/Rheumatoid Arthritis
- Simponi (Golimumab)
  Rheumatoid Arthritis/Ulcerative Colitis/Psoriasis
- Skyrizi (Risankizumab)
  Chrohn's/Ulcerative Colitis/Psoriasis
- Tepezza (Teprotumumab-trbw)
  Thyroid eye disease
- Vyvgart (efgartigimod alfa + hyaluronidase)
  Myasthenia Gravis
- Xolair (Omalizumab)
  Moderate/Severe Persistent Asthma

Others may be available upon approval.